Laura Panjwani

Articles

Expert Discusses Promise of Quizartinib in AML

March 15th 2017

Mark Levis, MD, PhD, highlights the promise and potential challenges of the FLT3-inhibitor quizartinib in acute myeloid leukemia.

Pan-Kinase Inhibition Key to Midostaurin Benefit in AML

March 7th 2017

FLT3 targeted agents are emerging in the treatment of acute myeloid leukemia, and which specific agent will be most effective is highly dependent on whether a patient has been previously treated.

Immunotherapy Makes Comeback in RCC, But Challenges Remain

December 6th 2016

Robert G. Uzzo, MD, discusses the promise of immunotherapies as well as the challenges with using them across different indications in renal cell carcinoma.

Immunotherapy Combos on Horizon in First-Line RCC

December 1st 2016

Immunotherapy combinations have significant potential as treatment for patients with renal cell carcinoma.

Tumor-Treating Fields Make Significant Impact in GBM

December 1st 2016

It’s not often that oncologists get to be the first to utilize cutting-edge technology.

Third-Generation TKI Most Promising Option for Ph+ ALL

November 30th 2016

Tyrosine-kinase inhibitors have considerably improved survival outcomes for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Lead PALOMA-2 Author Says Results Will Boost Global Use of Palbociclib

November 28th 2016

Results from the phase III PALOMA-2 study—which demonstrated a significant progression-free survival advantage with palbociclib (Ibrance) plus letrozole compared with letrozole alone in ER-positive, HER2-negative metastatic breast cancer—were recently published in The New England Journal of Medicine.

Investigating EGFR Resistance Leads to New Therapies, Advances in NSCLC

November 23rd 2016

While resistance to EGFR-targeted therapies in non–small cell lung cancer presents a major challenge, there is a silver lining.

I-SPY 2 Paves the Way for Novel HER2-Targeted Agents in Breast Cancer

November 22nd 2016

There are a wide variety of novel agents currently being investigated in the neoadjuvant setting for patients with HER2-positive breast cancer.

Cetuximab Benefit, Tumor Sidedness Impact Still Unclear in mCRC

November 21st 2016

Alan P. Venook, MD, discusses key issues in metastatic colorectal cancer, including tumor sidedness and the conflicting data regarding the precise benefit of cetuximab in the frontline setting.

Expert Explains Sequencing Considerations for Regorafenib and TAS-102 in mCRC

November 18th 2016

For a long time, patients with metastatic colorectal cancer had poor outcomes and very limited treatment options, said Tanios Bekaii-Saab, MD.

New Options Emerge in Frontline, Adjuvant RCC Care

November 17th 2016

Therapeutic options for patients with renal cell carcinoma have increased rapidly in the past decade, yet the field is still poised to expand significantly in the coming years, said Robert S. Alter, MD.

HPV-Vaccinated Patients Require Less Frequent Cervical Cancer Screening

November 17th 2016

Women who have been vaccinated against HPV can undergo less-intensive cervical cancer screening than is currently recommended, according to new findings released from the Harvard T.H. Chan School of Public Health.

Newly Identified Molecular Subtypes Could Guide Treatment Decisions in Prostate Cancer

November 16th 2016

Researchers have identified 3 distinct molecular subtypes of primary prostate cancer that correlate with distant metastasis-free survival and response to radiation therapy.

Regorafenib Renews Hope in Hepatocellular Carcinoma

November 14th 2016

There has been renewed optimism in hepatocellular carcinoma with regorafenib, a novel second-line agent that is currently being considered for approval by the FDA.

Lack of Screening, Surveillance Leads to Rising HCC Rates in Hepatitis B Patients

November 13th 2016

Hepatocellular carcinoma‎ incidence continues to rise among patients with hepatitis B despite improvements in antiviral therapies, stressing the importance of screening and surveillance in this population.

Nilotinib/Trametinib Show Early Promise in BRAF/NRAS Wild-Type Melanoma

November 9th 2016

The combination of nilotinib and trametinib proved to be synergistic in BRAF/NRAS wild-type melanoma.

More Than Half of Cervical Cancer Patients Not Receiving Recommended Treatment

November 8th 2016

Results of a new study found that less than half of patients with advanced cervical cancer are receiving all 3 of the therapies considered standard of care for the disease: external beam radiation therapy, brachytherapy, and chemotherapy.

Immunotherapy, MEK Inhibitor Combo Effective for BRAF Wild-Type Melanoma

November 8th 2016

The combination of atezolizumab and cobimetinib may lead to a higher overall response and a longer progression-free survival than either agent alone in patients with metastatic melanoma.

Speed Critical With Anaplastic Thyroid Cancer Diagnosis, Treatment

November 3rd 2016

Enrolling clinical trials can be a long process, especially in rare diseases with limited patient populations. This is a particularly significant issue for patients with anaplastic thyroid cancer, an extremely rare and aggressive disease.